About Servier

With a strong international presence in 149 countries and a turnover of 4.615 billion euros in 2019, Servier employs 22,000 people worldwide.

Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs.

Being completely independent, the Group reinvests an average of 25% of turnover (excluding generics) in research and development and uses all its profits for growth.

Servier was created in 1954, and in 1964 Servier UK was the first subsidiary to open, with just two employees.

Our R&D is specialised in 5 major axes

Our products

For our portfolio of medicinal products
available in the UK, click on the following link.

See our products

Transparency

United Kingdom Disclosure of Transfers of Values

Servier is an independent research foundation with no shareholders and as such revenue from the sale of our medicines is directly invested back into the research and development of our future treatments.

Servier is proud to work with UK Healthcare Professionals (Doctors, Nurses, and Pharmacists) to help patients get the life enhancing medicines they need and fully support a transparent culture. Such collaborations are recognition of the world class medical expertise we have available in this country and facilitate the sharing of best practice across the UK and around the world. As a global company, we see this as part of our ethical responsibility.

The advice we receive from clinical experts ensures that our medicines of today and tomorrow truly meet the needs of patients.  The disclosure of transfers of values to Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) is part of the transparency initiative developed by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Association of the British Pharmaceutical Industry (ABPI). Servier adheres and fully supports the objectives promoted through this self-regulatory initiative and believes the outcome of this publication will contribute to a better insight into our interactions.

All of Servier’s Transfers of Values to HCPs and HCOs (along with our methological note) can be found on the ABPI’s publicly searchable database Disclosure UK accessible on their website.

The ABPI also has a ‘resources’ page containing information for use by HCPs and HCOs to help them understand how Disclosure UK works.

If you are a healthcare professional with an enquiry regarding a payment you have received from Servier, or your details in the database, please email datamanagementUK@servier.com

If you would like to contact Servier Laboratories Ltd (UK), or to find more information on the publication made by Servier in other countries please use the appropriate link below:

Press/Media enquiry
General enquiry
Other Countries

Patient Organisations

Patient organisations are non-profit making groups or charities, which offer information and valuable support on a wide range of medical conditions to people suffering from illness.

Servier UK works with a number of patient organisations to raise disease awareness and help give patients access to up-to-date information on their condition.

All financial support made by Servier Laboratories Limited to patient organisations is declared on all of the materials produced in connection with the item or event as required by the ABPI Code of Practice.

 

Details of Patient Organisations we supported in 2019
Details of Patient Organisations we supported in 2018
Details of Patient Organisations we supported in 2017
Details of Patient Organisations we supported in 2016

Clinical trials

Servier takes pride in its commitment to Research and Development, regularly investing more than 25% of its annual turnover into advancing therapeutic innovations for patients.  A proportion of this research is done through clinical trials.

Servier conducts clinical trials for its products through a number of therapeutic research centres all over the world.  Servier UK Clinical Operations Department is currently involved in a number of trials in several therapeutic areas including leukaemia, lymphoma, colorectal cancer as well as in neuropsychiatry.

Servier’s interventional clinical trials are registered on this registry:

INVESTIGATOR INTIATED TRIALS

Servier is dedicated to supporting research that helps advance medical and scientific knowledge. As part of our commitment to research we recognise the valuable role of investigator initiated trials (IITs).  IITs are clinical studies initiated and managed by non-pharmaceutical company researchers e.g. individual researchers, institutions or collaborative study groups.

Servier may be able to support such studies by providing grant funding, and/or drug supply depending on the type of research. 

If you are from the UK and are interested in discussing research questions or submitting your ideas, email us at Medical.Information-UK@Servier.com

Please note that proposals are reviewed based on their scientific merit, research priorities, and available resources. Submission of a request does not guarantee approval.  

Supporting the NHS, Supporting Healthcare Professionals, Supporting Patients

Servier Laboratories is committed to supporting the NHS and Healthcare Professionals (HCPs) to enhance the care of patients within the UK.  Servier’s priority is to invest into clinical research which provides life changing treatments for patients with chronic conditions whilst also providing support to Healthcare Organisations (HCOs) through the provision of Medical and Educational Goods and Services. 

WHAT ARE MEDICAL AND EDUCATIONAL GOODS AND SERVICES OR ‘MEGS’?

MEGS are activities or the funding of activities, by industry, which are designed and intended to enhance patient care or benefit the NHS whilst maintaining patient care.  MEGS are unrelated to any promotional or commercial activities and may be provided subject to the regulations outlined in the Association of British Pharmaceutical Industry Code of Practice.  

WHY DOES SERVIER SUPPORT MEGS?

Servier’s priority is to continue our research and development of new medicines to help patients.  Where finance and regulations allow us, supporting patients and healthcare professionals in the wider management of the conditions in which we conduct research is something we take great pride in.  Whilst Servier cannot fund all projects that support education or patient care we are pleased to consider them.

Activities we will consider are those with a clear benefit to patients or the NHS, are in line with our research areas (Oncology and Haematology) and are not requests for payments to any specific individual.  We would like to support as many HCOs as possible, so if your organisation has received support in the past it may not always be possible to provide support for subsequent years.

SUPPORTING HCPs TO ATTEND EDUCATIONAL CONFERENCES

Servier supports the education of UK HCPs by allocating a set budget to fund the attendance at educational conferences.  Funding of an individual HCP may be considered where there is a clear benefit to UK patients or the NHS.  Funding requests for a financial contribution to cover an individual’s expenses to attend a conference, particularly if Servier is not in attendance, are unlikely to be accepted.  Retrospective requests for funding to attend a meeting will be rejected.

APPLYING TO SERVIER FOR MEGS FUNDING

If you represent a HCO or are a HCP operating within the NHS and are interested in applying for funding through a MEGS grant, please contact us at MEGSrequests-uk@servier.com

HOW ARE DECISIONS TO SUPPORT MEGS MADE ?

Requests for MEGS are reviewed by the MEGS committee on a monthly basis.  The MEGS committee is formed of senior employees from General Management, Regulatory Affairs, Medical Affairs and Compliance.

The following factors are taken into consideration –

  • clearly benefits patients
  • clearly benefits the NHS
  • related to an area of research in which Servier is active (cardiovascular, cancer, diabetes, immune-inflammatory and neuropsychiatric diseases)
  • the level of funding requested
  • the MEGS budget available that month